Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact

Complements Presence In Ex Vivo And Cell Therapy

 
• By Andrew McConaghie
  
Vertex Mobile
Vertex is investing in cell therapy and ex vivo and in vivo gene editing platforms. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip